PE20011307A1 - Una composicion farmaceutica que comprende un agonista de receptores de nicotina y un analgesico util para el tratamiento del dolor agudo, cronico y/o el dolor neuropatico y las migranas - Google Patents

Una composicion farmaceutica que comprende un agonista de receptores de nicotina y un analgesico util para el tratamiento del dolor agudo, cronico y/o el dolor neuropatico y las migranas

Info

Publication number
PE20011307A1
PE20011307A1 PE2001000319A PE2001000319A PE20011307A1 PE 20011307 A1 PE20011307 A1 PE 20011307A1 PE 2001000319 A PE2001000319 A PE 2001000319A PE 2001000319 A PE2001000319 A PE 2001000319A PE 20011307 A1 PE20011307 A1 PE 20011307A1
Authority
PE
Peru
Prior art keywords
chronic
acute
treatment
migrans
pharmaceutical composition
Prior art date
Application number
PE2001000319A
Other languages
English (en)
Inventor
Jotham Wadsworth Coe
Edmund Patrick Harrigan
Erick Jacob Watsky
Steven Bradley Sands
Brian Thomas O'neill
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20011307A1 publication Critical patent/PE20011307A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION UTIL PARA EL TRATAMIENTO DE DOLOR AGUDO, CRONICO, NEUROPATICO, MIGRANA, QUE COMPRENDE: a)UN AGONISTA PARCIAL DE RECEPTORES DE NICOTINA COMO 9-BROMO-1,2,3,4,5,6-HEXAHIDRO-1,5-METANO-PIRIDO [1,2-a][1,5]DIAZOCIN-8-ONA, 9-CLORO-1,2,3,4,5,6-HEXAHIDRO-1,5-METANO-PIRIDO [1,2-a][1,5]DIAZOCIN-8-ONA, ENTRE OTROS; b)UN ANALGESICO COMO PROPOXIFENO, MEPERIDINA, HIDROMORFONA, HIDROCODONA, MORFINA, CODEINA, TRAMADOL, 2-PIPERIDINO-1-ALCANOL, DEXTROMETORFANO, ELIPRODIL, IFENPRODIL, 6-METOXI-3-TRIFLUOROMETIL-BENZO[d]ISOXAZOL-5-ILMETIL)-(2-FENIL-PIPERIDIN-3-IL)AMINA, ROFECOXIB, CELECOXIB, OXIDO NITROSO, HALOTANO, LIDOCAINA, ETIDOCAINA, ROPIVACAINA, CLOROPROCAINA, SARAPINA, BUPIVACAINA, DIAZEPAM, CLORDIAZEPOXIDO, ALPRAZOLAM, LORAZEPAM, FLEXERIL, GABAPENTINA, PREGABALINA, ACIDO SALICILICO, BACLOFENO, CLONIDINA, PREDNISONA; c)UN VEHICULO
PE2001000319A 2000-04-07 2001-04-05 Una composicion farmaceutica que comprende un agonista de receptores de nicotina y un analgesico util para el tratamiento del dolor agudo, cronico y/o el dolor neuropatico y las migranas PE20011307A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19573800P 2000-04-07 2000-04-07

Publications (1)

Publication Number Publication Date
PE20011307A1 true PE20011307A1 (es) 2001-12-28

Family

ID=22722582

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000319A PE20011307A1 (es) 2000-04-07 2001-04-05 Una composicion farmaceutica que comprende un agonista de receptores de nicotina y un analgesico util para el tratamiento del dolor agudo, cronico y/o el dolor neuropatico y las migranas

Country Status (35)

Country Link
US (2) US20010036943A1 (es)
EP (1) EP1272218B1 (es)
JP (1) JP2003530345A (es)
KR (1) KR20030040201A (es)
CN (1) CN1468111A (es)
AP (1) AP2002002642A0 (es)
AR (1) AR027773A1 (es)
AT (1) ATE291438T1 (es)
AU (1) AU3768001A (es)
BG (1) BG107138A (es)
BR (1) BR0109837A (es)
CA (1) CA2405142A1 (es)
CR (1) CR6767A (es)
CZ (1) CZ20023214A3 (es)
DE (1) DE60109589T2 (es)
EA (1) EA004930B1 (es)
EE (1) EE200200579A (es)
ES (1) ES2236185T3 (es)
GT (1) GT200100055A (es)
HU (1) HUP0301822A3 (es)
IL (1) IL152076A0 (es)
IS (1) IS6560A (es)
MA (1) MA26889A1 (es)
MX (1) MXPA02009817A (es)
NO (1) NO20024734D0 (es)
OA (1) OA12241A (es)
PA (1) PA8515001A1 (es)
PE (1) PE20011307A1 (es)
PL (1) PL365957A1 (es)
SK (1) SK13952002A3 (es)
SV (1) SV2002000377A (es)
TN (1) TNSN01053A1 (es)
WO (1) WO2001076576A2 (es)
YU (1) YU74602A (es)
ZA (1) ZA200207996B (es)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0934061T6 (en) 1996-07-24 2015-01-26 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US7074961B2 (en) 2000-09-26 2006-07-11 The Brigham And Women's Hospital, Inc. Antidepressants and their analogues as long-acting local anesthetics and analgesics
JP2004524270A (ja) * 2000-09-26 2004-08-12 ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド 長時間作用する麻酔薬および鎮痛薬としての、三環式抗うつ薬およびのそれらのアナログ
IL157881A0 (en) * 2001-04-20 2004-03-28 Pfizer Prod Inc Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
PT2266558T (pt) * 2001-06-07 2017-07-21 Analgesic Neuropharmaceuticals Llc Tratamento da dor neuropática com o antagonista dos recetores de n-metil-d-aspartato (nmda) dextrometorfano
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20040138239A1 (en) * 2001-08-23 2004-07-15 Bruce Frome Compositions and methods for targeting cerebral circulation and treatment of headache
EP1419161A1 (en) 2001-08-24 2004-05-19 PHARMACIA & UPJOHN COMPANY Substituted-heteroaryl-7-aza 2.2.1]bicycloheptanes for the treatment of disease
PL369895A1 (en) 2001-10-02 2005-05-02 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
EP1442037A1 (en) 2001-11-09 2004-08-04 PHARMACIA & UPJOHN COMPANY Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
WO2003049753A1 (en) * 2001-12-13 2003-06-19 Council Of Scientific And Industrial Research Bioavailability enhancing activity of zingiber officinale linn and its extracts/fractions thereof
MXPA04006882A (es) * 2002-01-17 2004-12-06 Neurogen Corp Analogos substituidos de quinazolin-4-ilamina como moduladores de receptores de capsaicina.
AU2003207219A1 (en) 2002-02-05 2003-09-02 Ajinomoto Co., Inc. Medicinal compositions containing gabapentin or pregabalin and n-type calcium channel antagonist
CA2475763A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
MXPA04007936A (es) 2002-02-15 2004-11-26 Upjohn Co Compuestos de aril-sustituidos para el tratamiento de enfermedades.
JP2005523288A (ja) 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
WO2003070731A2 (en) 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US20040014681A1 (en) * 2002-05-14 2004-01-22 Ralph Ryback Method for treating dermatoses and tissue damage
JP2006504634A (ja) * 2002-05-15 2006-02-09 アボット・ラボラトリーズ 神経障害性疼痛の治療
EP1507826A4 (en) 2002-05-17 2007-11-07 Othera Pharmaceuticals Inc IMPROVING THE EVOLUTION OF CATARACTS AND OTHER OPHTHALMIC DISEASES
AU2003280393A1 (en) * 2002-10-17 2004-05-04 Novartis Ag Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors
EP2412719A1 (en) 2002-12-02 2012-02-01 Xenome Ltd Chi-conotoxin peptides
WO2004050690A1 (en) 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-I)
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
ATE359075T1 (de) 2002-12-20 2007-05-15 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
US8691769B2 (en) * 2003-03-06 2014-04-08 Botulinum Toxin Research Associates, Inc. Treatment of sinusitis related chronic facial pain and headache with botulinum toxin injections
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
CA2521925A1 (en) * 2003-04-08 2004-10-28 Algorx Pharmaceuticals, Inc. Preparation and purification of synthetic capsaicin
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
WO2005000806A2 (en) 2003-06-10 2005-01-06 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
US20050004219A1 (en) * 2003-07-01 2005-01-06 Medtronic, Inc. Pump systems including injectable gabapentin compositions
US20050004221A1 (en) * 2003-07-01 2005-01-06 Medtronic, Inc. Intrathecal gabapentin compositions
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CA2930900C (en) 2003-10-02 2018-10-16 Jazz Pharmaceuticals International Limited Combinations of ziconotide and opioids for reducing pain
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
CA2543315A1 (en) * 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
HU230403B1 (hu) * 2003-12-19 2016-04-28 Pál Kocsis Nátrium csatorna blokkoló és szerotonin újrafelvétel gátló tartalmú gyógyszerkészítmény
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
EP1765300A2 (en) * 2004-06-10 2007-03-28 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US8940311B2 (en) * 2004-10-21 2015-01-27 Tae-Hong Lim In situ controlled release drug delivery system
WO2006053012A2 (en) * 2004-11-10 2006-05-18 Trinity Laboratories, Inc. Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria
CA2596194A1 (en) * 2004-11-24 2006-06-01 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
CA2609185A1 (en) 2005-05-20 2006-11-30 Ahmed F. Abdel-Magid Process for preparation of sulfamide derivatives
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
EP1998748B1 (en) 2006-03-16 2015-01-14 NicoNovum AB Improved snuff composition
JP2007308403A (ja) * 2006-05-17 2007-11-29 Kenji Yoshida 皮膚外用剤
TW200812573A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
EP2051735B1 (en) * 2006-07-17 2012-08-29 Ramot, at Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders
JPWO2008020651A1 (ja) * 2006-08-17 2010-01-07 国立大学法人九州大学 Ｐ２ｘ４受容体アンタゴニスト
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
WO2008036858A2 (en) * 2006-09-20 2008-03-27 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
WO2008073381A2 (en) * 2006-12-11 2008-06-19 University Of Kentucky Research Foundation Synergistic effects of combinations of nornicotine and opioids for the treatment of pain
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
CN101855218A (zh) 2007-09-13 2010-10-06 康塞特医药品有限公司 氘化的儿茶酚和苯并[d][1,3]间二氧杂环戊烯及其衍生物的合成
WO2009095877A2 (en) * 2008-01-31 2009-08-06 Fund For Medical Research Development Of Infrastructure And Health Services Rambam Medical Center Method of predicting pain medication efficacy
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
ES2604968T3 (es) 2008-04-28 2017-03-10 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
AU2011267474B2 (en) 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
AU2011346757B2 (en) 2010-12-22 2015-08-20 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
JP5638151B2 (ja) 2010-12-23 2014-12-10 パーデュー、ファーマ、リミテッド、パートナーシップ 不正加工抵抗性の（ｔａｍｐｅｒｒｅｓｉｓｔａｎｔ）固形経口剤形
US20130324608A1 (en) * 2011-02-18 2013-12-05 Yuanlong Pan Methods and compositions for treating, reducing or preventing damage to the nervous system of animals
ES2387973B1 (es) * 2011-03-18 2013-10-01 Dr Healthcare España, S. L. Composiciones tópicas que contienen diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que comportan un aumento del dolor.
WO2013023155A1 (en) 2011-08-11 2013-02-14 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use
JP6262732B2 (ja) * 2012-08-16 2018-01-17 ヤンセン ファーマシューティカ エヌ．ベー． Ｎ型カルシウムチャネル遮断剤としての置換ピラゾール
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN104758933A (zh) * 2014-10-29 2015-07-08 吴鑫欣 治疗神经卡压、神经瘤疼痛的药物和给药系统
US20200023044A1 (en) * 2017-03-22 2020-01-23 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
WO2018183320A1 (en) * 2017-03-31 2018-10-04 Depco, Inc. Therapeutic putty having analgesics and/or counterirritants
CA3059435A1 (en) * 2017-04-12 2018-10-18 Synergistic Therapeutics, Llc Therapeutic neuropathic pain lotion
KR101944113B1 (ko) 2017-09-28 2019-01-30 동의대학교 산학협력단 급성 안면통증 예방 및 개선용 조성물
KR102156438B1 (ko) 2018-12-20 2020-09-16 동의대학교 산학협력단 급성 안면통증 예방 및 개선용 조성물
KR102156627B1 (ko) 2018-12-20 2020-09-16 동의대학교 산학협력단 보스웰리아 추출물 및 산자나무 추출물을 포함하는 급성 안면통증 예방 및 개선용 조성물
CN115054601B (zh) * 2022-03-21 2024-04-26 中山大学附属第三医院 一种可注射的缓释镇痛复合物及其制备方法、应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2264169T3 (es) * 1996-10-30 2006-12-16 Pfizer Inc. Derivados azabiciclicos de piridona fusionada o de citisina, su preparacion y su uso en la terapia de adiccion.
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
PT1076650E (pt) * 1998-04-29 2004-05-31 Pfizer Prod Inc Compostos azapoliciclicos fundidos com arilo
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
EA004930B1 (ru) 2004-10-28
SV2002000377A (es) 2002-07-03
HUP0301822A3 (en) 2005-06-28
EP1272218A2 (en) 2003-01-08
NO20024734D0 (no) 2002-10-02
MA26889A1 (fr) 2004-12-20
ATE291438T1 (de) 2005-04-15
ZA200207996B (en) 2003-10-20
EP1272218B1 (en) 2005-03-23
EA200200910A1 (ru) 2003-02-27
GT200100055A (es) 2001-12-31
IS6560A (is) 2002-09-20
OA12241A (en) 2004-01-27
CR6767A (es) 2004-06-09
DE60109589D1 (de) 2005-04-28
YU74602A (sh) 2006-05-25
PL365957A1 (en) 2005-01-24
WO2001076576A2 (en) 2001-10-18
CA2405142A1 (en) 2001-10-18
KR20030040201A (ko) 2003-05-22
IL152076A0 (en) 2003-05-29
MXPA02009817A (es) 2003-03-27
US20010036943A1 (en) 2001-11-01
PA8515001A1 (es) 2002-02-21
CZ20023214A3 (cs) 2003-11-12
WO2001076576A3 (en) 2002-06-20
ES2236185T3 (es) 2005-07-16
JP2003530345A (ja) 2003-10-14
AP2002002642A0 (en) 2002-12-31
TNSN01053A1 (fr) 2005-11-10
AR027773A1 (es) 2003-04-09
CN1468111A (zh) 2004-01-14
BG107138A (en) 2003-05-30
AU3768001A (en) 2001-10-23
US20030133951A1 (en) 2003-07-17
BR0109837A (pt) 2003-01-21
DE60109589T2 (de) 2005-09-01
HUP0301822A2 (hu) 2003-11-28
EE200200579A (et) 2004-06-15
SK13952002A3 (sk) 2003-12-02

Similar Documents

Publication Publication Date Title
PE20011307A1 (es) Una composicion farmaceutica que comprende un agonista de receptores de nicotina y un analgesico util para el tratamiento del dolor agudo, cronico y/o el dolor neuropatico y las migranas
ES2449222T3 (es) Análogos de buprenorfina
ATE487477T1 (de) Nicht-sedierender a-2 agonist 1-(2,3-dimethyl- phenyl)-ethyl-1, 3-dihydro-imizadol-2-thion
BRPI0708490B8 (pt) composto, composição farmacêutica, processo para preparar um composto da fórmula (i), e uso de um composto
ATE426399T1 (de) Missbrauchsichere transdermale abgabevorrichtung fur opioide, enthaltend opioidantagonist in form von mikrokugelchen
ATE406360T1 (de) Antagonisten der opioidrezeptoren
CY1109139T1 (el) Συνδυασμοι που περιλαμβανουν αντιμουσκαρινικους παραγοντες και βητα-αδρενεργικους αγωνιστες
RU2009125597A (ru) Пролекарства и способы их получения и применения
ATE396999T1 (de) Morphinanderivate substituiert in position 14 und deren quartäre ammoniumsalze, herstellungsverfahren und verwendung
ATE303369T1 (de) Glucocorticoid rezeptor modulatoren
PE20050772A1 (es) Piperidinilcarbonil-pirrolidinas como agonistas de melanocortina
TNSN08027A1 (en) Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use of same
SI2961407T1 (en) Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2 (1h) -one derivatives of the beta2 adrenergic beta2 agonist activity and also of muscarinic receptor antagonists
ATE327974T1 (de) Modulatoren des glucocorticoid-rezeptors
PE20071034A1 (es) Compuestos heterociclicos como inhibidores de cetp
DE60302157D1 (de) Opioidrezeptorantagonisten
ATE403426T1 (de) Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
Hipskind et al. 3-Aryl-1, 2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists
WO2020055725A4 (en) Dopamine d3 receptor selective antagonists/partial agonists and uses thereof
DE60137451D1 (de) N-substituierte Amide als NK1 Rezeptor Antagonisten
PE20001550A1 (es) Procedimiento para preparar secretagogos de hormonas del crecimiento
Calderon Nonpeptidic delta (δ) opioid agonists and antagonists of the diarylmethylpiperazine class: What have we learned?
Kormos et al. Effect of the 3-and 4-methyl groups on the opioid receptor properties of N-substituted trans-3, 4-dimethyl-4-(3-hydroxyphenyl) piperidines
RU2220713C1 (ru) Анальгезирующее, спазмолитическое, противовоспалительное лекарственное средство
PE20020041A1 (es) Combinacion farmaceutica que comprende un compuesto de efecto opioide y un compuesto peptidico

Legal Events

Date Code Title Description
FD Application declared void or lapsed